Cocrystal Pharma (NASDAQ:COCP) Announces Quarterly Earnings Results

Cocrystal Pharma (NASDAQ:COCP) posted its quarterly earnings data on Tuesday. The company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.01, FiscalAI reports.

Cocrystal Pharma Stock Performance

Shares of COCP opened at $1.00 on Tuesday. The company’s 50 day moving average price is $1.02 and its 200 day moving average price is $1.07. Cocrystal Pharma has a 52 week low of $0.86 and a 52 week high of $2.67. The company has a market capitalization of $13.78 million, a PE ratio of -1.06 and a beta of 1.18.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cocrystal Pharma in a report on Monday, December 22nd. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $6.00.

Insider Transactions at Cocrystal Pharma

In related news, Director Phillip Md Et Al Frost bought 50,000 shares of the firm’s stock in a transaction on Friday, February 6th. The stock was bought at an average price of $0.95 per share, with a total value of $47,500.00. Following the purchase, the director directly owned 1,888,551 shares of the company’s stock, valued at approximately $1,794,123.45. This represents a 2.72% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 28.14% of the stock is currently owned by insiders.

Institutional Trading of Cocrystal Pharma

An institutional investor recently bought a new position in Cocrystal Pharma stock. DRW Securities LLC bought a new stake in Cocrystal Pharma, Inc. (NASDAQ:COCP) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 33,593 shares of the company’s stock, valued at approximately $33,000. DRW Securities LLC owned approximately 0.24% of Cocrystal Pharma at the end of the most recent reporting period. Institutional investors and hedge funds own 6.72% of the company’s stock.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.